



November 22, 2019

**BSE Limited,**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards launch of Hydrocortisone Valerate Cream USP, 0.2%, which is the generic equivalent of Westcort® Cream, 0.2%, of Sun Pharmaceutical Industries Inc. having received an approval from the U.S. FDA earlier.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**



Encl.: a/a

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin launches Hydrocortisone Valerate Cream

**Mumbai, Baltimore, November 22, 2019:** Pharma major Lupin Limited (Lupin) announced the launch of Hydrocortisone Valerate Cream USP, 0.2%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Lupin's Hydrocortisone Valerate Cream USP, 0.2%, is the generic equivalent of Westcort® Cream, 0.2%, of Sun Pharmaceutical Industries Inc. It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Hydrocortisone Valerate Cream USP, 0.2%, (RLD: Westcort® Cream) had an annual sales of approximately USD 11.5 million in the U.S. (IQVIA MAT September 2019).

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8<sup>th</sup> largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3<sup>rd</sup> largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); 6<sup>th</sup> largest company in the Indian Pharmaceutical Market and 5<sup>th</sup> largest generic pharmaceutical player in Japan (IQVIA MAT September 2019).

For the financial year ended March 31, 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter at – [www.twitter.com/lupinglobal](https://www.twitter.com/lupinglobal)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

### For further information or queries please contact-

Arvind Bothra

Head – Investor Relations and M&A / Corporate Communications

Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

Ph: +91-22-66408237

### **\*Safe Harbor Statement**

*Westcort® is a registered trademark of Sun Pharmaceutical Industries Inc.*